Protalix BioTherapeutics (PLX) Tax Provisions (2023 - 2026)

Protalix BioTherapeutics' Tax Provisions history runs 4 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• On a quarterly basis, Tax Provisions rose 2536.28% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $2.7 million, a 115.0% increase from a year earlier, with the FY2025 full-year figure at $105000.0, down 91.41% from the prior year.
• Tax Provisions climbed to $2.8 million in Q1 2026 per PLX's latest filing, from -$163000.0 in the prior quarter.
• Across five years, Tax Provisions topped out at $3.4 million in Q2 2023 and bottomed at -$1.9 million in Q4 2023.
• The 4-year median for Tax Provisions is $133000.0 (2023), against an average of $432846.2.
• Across the five-year window, Tax Provisions plunged 170.77% in 2024 and surged 2536.28% in 2026, its largest moves.
• Year by year, Tax Provisions stood at -$1.9 million in 2023, then surged by 154.85% to $1.1 million in 2024, then slumped by 115.41% to -$163000.0 in 2025, then jumped by 1788.96% to $2.8 million in 2026.
• Per Business Quant, the three latest PLX Tax Provisions figures stand at $2.8 million (Q1 2026), -$163000.0 (Q4 2025), and -$175000.0 (Q3 2025).